## Androgen receptor signaling promotes Treg suppressive function during allergic airway inflammation

Vivek D. Gandhi<sup>1\*</sup>, Jacqueline-Yvonne Cephus<sup>1\*</sup>, Allison E. Norlander<sup>1</sup>, Nowrin U. Chowdhury<sup>2</sup>, Jian Zhang<sup>1</sup>, Zachary Ceneviva<sup>1</sup>, Elie Tannous<sup>1</sup>, Vasiliy V Polosukhin<sup>1</sup>, Nathan D. Putz<sup>1</sup>, Nancy Wickersham<sup>1</sup>, Amrit Singh<sup>3</sup>, Lorraine B. Ware<sup>1</sup>, Julie A. Bastarache<sup>1</sup>, Ciara M. Shaver<sup>1</sup>, Hong Wei Chu<sup>4</sup>, R. Stokes Peebles, Jr.<sup>1,2</sup>, Dawn C. Newcomb<sup>1,2</sup>

 <sup>1</sup> Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
<sup>2</sup> Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
<sup>3</sup> Prevention of Organ Failure (PROOF) Centre of Excellence, University of British Columbia, Vancouver, BC, Canada
<sup>4</sup>National Jewish Medical Center, Denver, CO, USA

\* contributed equally to this work.


Corresponding author: Dawn C. Newcomb, PhD T-1218 Medical Center North 1161 21<sup>st</sup> Avenue South Nashville, TN 37232 (615) 875-7782

dawn.newcomb@vumc.org


Conflicts of interest: The authors have declared that no conflict of interest exists.


## Supplement Table – Antibodies, viability dyes, and isolation kits used in this project

Reagent	Antibody target	Clone	Fluorophore	Manufacturer	Catalog Number
anti-mouse antibody	Bcl6	K112-91	Alexa Fluor 647	BD Biosciences	561525
anti-mouse antibody	CD16/CD32	2.4G2	Purified	<b>BD Biosciences</b>	553142
anti-mouse antibody	CD25	PC61	APC-Cy7	<b>BD Biosciences</b>	557658
anti-mouse antibody	CD28	37.51	Ultra-LEAF purified	BioLegend	102116
anti-mouse antibody	CD3	17A2	Alexa Fluor 700	BioLegend	100216
anti-mouse antibody	CD3	145-2C11	APC-Cy7	<b>BD Biosciences</b>	557596
anti-mouse antibody	CD3e	145-2C11	Ultra-LEAF purified	BioLegend	100340
anti-mouse antibody	CD4	GK1.5	Alexa Fluor 700	BioLegend	100429
anti-mouse antibody	CD4	GK1.5	FITC	eBioscience	11-0041-82
anti-mouse antibody	CD4	H129.19	PE-Cy5	<b>BD Biosciences</b>	553654
anti-mouse antibody	CD4	RM4-5	PE-Cy7	BioLegend	100527
anti-mouse antibody	CD4	RM4-5	PerCP-Cy5.5	<b>BD Biosciences</b>	550954
anti-mouse antibody	CD90	53-2.1	Brilliant Violet 786	<b>BD Biosciences</b>	564365
anti-mouse antibody	CTLA4	UC10- 4F10-11	APC	BD Biosciences	564331
anti-mouse antibody	DO11.10 TCR	KJ126	Biotin	eBioscience	13-5808-82
anti-mouse antibody	ICOS	C398.4A	PE-Cy7	eBioscience	25-9949-82
anti-mouse antibody	IL-13	eBio13A	PerCP-Cy5.5	eBioscience	46-7133-80
anti-mouse antibody	LAG-3	C9B7W	Brilliant Violet 786	<b>BD Biosciences</b>	740959
anti-mouse antibody	ST2	U29-93	Brilliant Violet 421	<b>BD Biosciences</b>	566309
anti-mouse antibody	ST2	U29-93	PE	<b>BD Biosciences</b>	566311
anti-mouse antibody	Streptavidin		PECF594	<b>BD Biosciences</b>	562284
anti-human antibody	CD2, CD3, and CD28		T Cell Activation/Expansion Kit, human	Miltenyi Biotec	130-091-441
anti-human antibody	CD25	BC96	APC-Cy7	BioLegend	302614
anti-human antibody	CD3	UCHT1	PacBlue	<b>BD Biosciences</b>	558117
anti-human antibody	CD4	SK3	FITC	<b>BD Biosciences</b>	562970
anti-human antibody	CD45	HI30	redFluor 710 (AF700)	Tonbo Biosciences	80-0459
anti-human antibody	ST2		APC	R&D Systems	FAB5231A
anti-mouse/human antibody	Foxp3	FJK-16S	PE-Cy7	eBioscience	25-5773-82
anti-mouse/human antibody	GATA3	L50-823	PECF594 (TxREd)	<b>BD Biosciences</b>	563510
Cell viability dye			Live/Dead Aqua	ThermoFisher	L34957
Cell viability dye			Ghost Dye UV 450	Tonbo Biosciences	13-0868
Cell viability dye			Ghost Dye Violet 510	Tonbo Biosciences	13-0870
Cell proliferation dye			Cell Trace Violet	ThermoFisher	C34571
CD4+ CD62L+ naïve T cell isolation kit				Miltenyi Biotec	130-106-643
CD4+ T cell isolation kit				Miltenyi Biotec	130-104-454




Supplemental Figure 1. Gating strategy for identification of Tregs (CD3+ CD4+ Foxp3+) and Th2 cells (CD3+ CD4+ GATA3+). Representative sample showing gating strategy.






Supplemental Figure 2. Testosterone decreases Alt Ext induced allergic inflammation and increases Treg to Th2 cell ratio. Sham-operated C57BL/6J male and female mice and gonadectomized male mice underwent the Alt Ext protocol. BAL fluid and lungs were harvested 1 day following the last challenge. (A-B). Eosinophils and neutrophils in BAL fluid. (C) Representative dots plots showing gating for Tregs and Th2 cells in lung (cells were pre-gated on viable, CD3+ CD4+ cells). (D-F). Quantification of Tregs, Th2, and the Treg to Th2 ratio. Data are mean  $\pm$  SEM; n = 4-5, \* p<0.05, ANOVA with Tukey post-hoc.




## Supplemental Figure 3. Male Tregs are more suppressive than female Tregs in $D011.10 \times Foxp3^{EGFP}$ mice. Treg suppression assay using Tregs from $D011.10 \times Foxp3^{EGFP}$ female or male mice and T effector cells (Teffs) from D011.10 female mice.


Percent suppression of Tregs at various ratios of Tregs to Teffs. Data are mean  $\pm$  SEM; n = 3, representative data from 2 experiments \* p<0.05, ANOVA with Tukey post-hoc.




**Supplemental figure 4. PCR verification of AR deficiency in Tregs.** PCR was conducted on testes and splenic Tregs from  $Ar^{fl/0}$  and  $Ar^{fl/0} \times Foxp3^{Cre+}$  male mice. Water was used as a negative control.




Supplemental figure 5. AR signaling decreases Alt Ext-induced airway inflammation in *Foxp3*<sup>GFP/YFP</sup> x *II13*<sup>Tdtomato</sup> mice. (A-B) BAL eosinophils and neutrophils in female and male *Foxp3*<sup>GFP/YFP</sup> x *II13*<sup>Tdtomato</sup> mice. (C-F) *Foxp3*<sup>GFP/YFP</sup> x *II13*<sup>Tdtomato</sup> male mice underwent gonadectomy or sham operation at 3-4 weeks of age. At 8 weeks old, 5 $\alpha$ -DHT (DHT) or vehicle slow-release pellets were subcutaneously placed into mice. After 3 weeks, mice underwent Alt Ext protocol. (C-D) BAL eosinophils and neutrophils. (E-F) IL-5 and IL-13 levels in whole lung homogenates. Data are mean ± SEM; n = 6-10 from 2 separate experiments, \* p<0.05, ANOVA with Tukey post-hoc.



Supplemental figure 6. Males have decreased numbers of ST2+ Tregs after Alt Ext challenge. (A) Representative histograms of ST2+ current Tregs, ex-Tregs, or Th2 cells from  $Foxp3^{GFP/YFP} \times II13^{Tdtomato}$  female and male mice. (B-D) Numbers of ST2+ current Tregs, ex-Tregs, and IL-13+ Th2 cells in lungs of mice. (E-G) ST2 MFI. Data are mean ± SEM; n = 6-10 from 2 separate experiments, \* p<0.05, ANOVA with Tukey post-hoc.



**Supplemental Figure 7. Gating strategy for identification** *IL-33*<sup>EGFP</sup>**+ cells.** Representative dot plots showing that epithelial cells were identified as CD45- EpCAM+, endothelial cells were identified as CD45- EpCAM- CD146+, and immune cells were identified as CD45+ cells.



**Supplemental Figure 8. AR signaling increases Bcl6+ Tregs.** Bcl6+ Tregs were determined from rmIL-33 challenged female, male, and  $Ar^{Tfm}$  male mice. Data are mean ± SEM; n = 3-5, \* p<0.05, ANOVA with Tukey post-hoc.